VRTX FY 2024 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11.0B+11.7% YoY

Gross Profit

$9.5B86.1% margin

Operating Income

-$233M-2.1% margin

Net Income

-$536M-4.9% margin

EPS (Diluted)

$-2.08

Cash Flow

Operating Cash Flow

-$493M

Free Cash Flow

-$790M

Stock-Based Comp.

$699M

Balance Sheet

Total Assets

$22.5B

Total Liabilities

$6.1B

Stockholders' Equity

$16.4B

Cash & Equivalents

$4.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.0B	$9.9B	+11.7%
Gross Profit	$9.5B	$8.6B	+10.3%
Operating Income	-$233M	$3.8B	-106.1%
Net Income	-$536M	$3.6B	-114.8%